Medico Remedies (MEDICO) Share Price Falls 10.26% to Rs 35.52: What Today’s Decline Shows
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Medico Remedies Share Price fell to Rs 35.52 on 09 September 2026, down 10.26% for the day. The move reduced the stock by Rs 4.06 from its previous close of Rs 39.58 and took the company’s market capitalisation to Rs 328.45 crore. For investors tracking this micro-cap pharmaceutical counter, the decline stands out because it placed the stock close to the lower end of its intraday range.
The supplied market data shows that the stock opened at Rs 39.10, which was also the day’s high, and then declined to a low of Rs 35.41 before trading at Rs 35.52. Turnover stood at Rs 0.18 crore. The numbers clearly confirm the price move, but they do not establish a company-specific reason behind it. In other words, the decline is visible in the market data, while the immediate catalyst remains unconfirmed in the available dataset.
From a broader metrics perspective, Medico Remedies sits in the Healthcare sector under Pharmaceuticals & Drugs. It is classified as a Micro Cap company. Its current valuation and profitability snapshot includes a P/E ratio of 23.77, P/B ratio of 4.21, ROE of 17.58%, ROCE of 21.65%, EPS of Rs 1.66 and book value per share of Rs 9.40. These figures help frame today’s weakness beyond only the one-session price action.
Medico Remedies (MEDICO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 35.52 |
| Previous Close | Rs 39.58 |
| Today's Move | -Rs 4.06 (-10.26%) |
| Open | Rs 39.1 |
| High | Rs 39.1 |
| Low | Rs 35.41 |
| Turnover | Rs 0.18 crore |
| Market Capitalisation | Rs 328.45 crore |
| Market Cap Category | Micro Cap |
Today’s trading pattern was notably weak. The stock opened at Rs 39.10 and never moved above that level, making the open and the day’s high identical. It then slipped to Rs 35.41 and remained near that lower band. That structure typically tells readers that selling pressure persisted through the session rather than easing after the initial move.
Another useful technical reference is the RSI reading of 44.88. On its own, that places the stock in a middle zone rather than an extreme one. The stock is also below both the 50-day DMA of 43.25 and the 200-day DMA of 43.53, which gives added context to the current weakness in trend terms. These figures do not predict what happens next, but they do show that the current traded price is below both medium- and longer-term moving average reference levels provided in the dataset.
Medico Remedies (MEDICO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 328.45 crore |
| P/E Ratio | 23.77x |
| P/B Ratio | 4.21x |
| ROE | 17.58% |
| ROCE | 21.65% |
| EPS | Rs 1.66 |
| Book Value Per Share | Rs 9.4 |
| Dividend Yield | 0% |
On earnings valuation, the company trades at 23.77 times earnings. That is below the Pharmaceuticals & Drugs industry median P/E of 32.19 and also below the industry average of 49.13 across 169 companies with available P/E data. This means the stock is not screening above the broader industry benchmark on earnings multiple alone.
Book-based valuation is somewhat different. The P/B ratio is 4.21, which is above the industry median of 3.05 but slightly below the industry average of 4.44. That creates a mixed valuation picture: earnings multiple looks lower than the industry centre, while the book multiple sits somewhat above the median benchmark.
Profitability ratios remain relatively stronger. ROE stands at 17.58%, higher than the industry median of 11.82% and average of 11.12%. ROCE at 21.65% is also above the median of 13.71% and average of 13.62%. EPS is Rs 1.66, book value per share is Rs 9.40 and dividend yield is 0, indicating that the supplied snapshot does not show a payout yield supporting the stock at present.
The company’s size is also relevant. Its market capitalisation of Rs 328.45 crore is below the industry median market cap of Rs 715.60 crore and far below the industry average of Rs 14,150.82 crore. That comparison reinforces that Medico Remedies is much smaller than the typical listed pharmaceutical name in the benchmark sample.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 23.77x |
| Benchmark Median P/E | 32.19x |
| Benchmark Average P/E | 49.13x |
| Benchmark P/E Range | 3.39x to 668.68x |
| Company P/B Ratio | 4.21x |
| Benchmark Median P/B | 3.05x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 17.58% |
| Benchmark Median ROE | 11.82% |
| Benchmark Average ROE | 11.12% |
| Company ROCE | 21.65% |
| Benchmark Median ROCE | 13.71% |
| Benchmark Average ROCE | 13.62% |
| Company Market Capitalisation | Rs 328.45 crore |
| Benchmark Median Market Cap | Rs 715.6 crore |
| Benchmark Average Market Cap | Rs 14,150.82 crore |
The same-industry benchmark covers 201 companies, giving a wider backdrop for reading the current decline. Relative to that group, the company appears smaller in scale, lower on P/E than the median and average, somewhat above the median on P/B, and stronger than the median on both ROE and ROCE. That combination suggests the stock’s valuation and profitability picture is not one-dimensional.
It is also important not to read the sector comparison as a short-term trigger. The benchmark data helps frame where the company sits in the industry, but it does not explain why the stock fell sharply in this session. The supplied dataset only confirms the move and the comparative metrics.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,55,825.66 | 37.31 | 5.22 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,018.51 | 86.86 | 14.38 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,86,874.73 | 86.55 | 21.03 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,211.69 | 25.42 | 4.25 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,773 | 33.17 | 3.18 | 11.83 | 16 |
Against selected peers, the biggest difference is scale. Medico Remedies’ market capitalisation of Rs 328.45 crore is far below Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, all of which are many orders larger in the supplied peer set.
On valuation, the company’s P/E of 23.77 is below Sun Pharma at 37.31, Divi’s at 86.86, Torrent at 86.55, Zydus Lifesciences at 25.42 and Cipla at 33.17. Its P/B of 4.21 is lower than Sun Pharma’s 5.22, Divi’s 14.38 and Torrent’s 21.03, close to Zydus at 4.25, and above Cipla at 3.18.
Profitability is mixed but competitive in parts. ROE of 17.58% is above Sun Pharma, Divi’s and Cipla, but below Zydus Lifesciences and Torrent. ROCE of 21.65% is above Sun Pharma, Torrent, Zydus Lifesciences and Cipla, and slightly above Divi’s 21.51%. That does not erase today’s decline, but it does show that the stock’s return ratios compare reasonably well with several larger peers in the provided list.
Why Investors Are Watching Medico Remedies
- The stock fell 10.26% in one session from Rs 39.58 to Rs 35.52.
- It opened at Rs 39.10, which was also the day’s high, and declined to Rs 35.41.
- RSI is 44.88, while the stock is below both the 50-DMA of 43.25 and the 200-DMA of 43.53.
- P/E of 23.77 is below the industry median of 32.19.
- ROE of 17.58% and ROCE of 21.65% are above broader industry medians.
- Its market cap of Rs 328.45 crore keeps it firmly in the Micro Cap category.
About Medico Remedies
Medico Remedies operates in the Healthcare sector and belongs to the Pharmaceuticals & Drugs industry. Based on the supplied context, it is a listed micro-cap pharmaceutical company rather than a large diversified healthcare major. That distinction matters because smaller companies can show sharper day-to-day price swings, while peer comparisons must be read with scale differences in mind.
Track Medico Remedies Share Price on Univest
UseMedico Remedies (MEDICO) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, users can monitor Medico Remedies Share Price alongside valuation ratios, profitability metrics and peer comparison data, helping place today’s decline in a broader analytical framework rather than viewing it in isolation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Medico Remedies Share Price falling today?
Ans. Medico Remedies Share Price fell 10.26% to Rs 35.52 from the previous close of Rs 39.58. The supplied data confirms the decline, but it does not establish any company-specific catalyst for today’s move.
What is Medico Remedies Share Price today?
Ans. The current traded price in the supplied snapshot is Rs 35.52. The stock is down Rs 4.06, or 10.26%, versus the previous close of Rs 39.58. The intraday range extended from Rs 35.41 to Rs 39.1.
What were the day’s trading levels for Medico Remedies?
Ans. The stock opened at Rs 39.10, touched a high of Rs 39.10 and declined to a low of Rs 35.41. It was trading at Rs 35.52 in the supplied update.
What is the market capitalisation of Medico Remedies?
Ans. Medico Remedies has a market capitalisation of Rs 328.45 crore. That places it in the Micro Cap category. The company operates in the Healthcare sector. Its P/E ratio is 23.77x.
Is Medico Remedies expensive based on P/E ratio?
Ans. The stock trades at a P/E ratio of 23.77, which is below the same-industry median of 32.19 and average of 49.13 in the supplied benchmark data. Its P/B ratio is 4.21x.
How does Medico Remedies compare on price to book?
Ans. Its P/B ratio is 4.21. That is above the industry median of 3.05, though slightly below the industry average of 4.44. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.
How strong are Medico Remedies’ profitability ratios?
Ans. ROE stands at 17.58% and ROCE at 21.65%. Both are above the Pharmaceuticals & Drugs industry medians in the provided dataset. The relevant peer median ROE is 11.82%. The relevant peer median ROCE is 13.71%.
What do EPS, book value and dividend yield show?
Ans. EPS is Rs 1.66, book value per share is Rs 9.40 and dividend yield is 0. These figures show earnings support and accounting net worth, but no payout yield in the snapshot.
How does Medico Remedies compare with larger pharma peers?
Ans. It is far smaller than peers such as Sun Pharma, Divi’s, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla by market value. However, its ROE and ROCE remain competitive versus several names in that peer set.
What should investors monitor after today’s fall?
Ans. Investors may watch whether the stock stabilises after trading near its intraday low, while also tracking valuation ratios, profitability metrics, RSI and its position relative to the 50-DMA and 200-DMA.
